Pediatric Epilepsy Study in Subjects 1-24 Months
Public ClinicalTrials.gov record NCT00044278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.
Study identification
- NCT ID
- NCT00044278
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 197 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Month to 24 Months
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2000 (Type not available)
- Primary completion
- Jun 2006 (Actual)
- Completion
- Jun 2006 (Actual)
- Last update posted
- Jan 18, 2017
2000 – 2006
United States locations
- U.S. sites
- 41
- U.S. states
- 21
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Mobile | Alabama | 36693 | — |
| GSK Investigational Site | Tucson | Arizona | 85712 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72202 | — |
| GSK Investigational Site | Los Angeles | California | 90027 | — |
| GSK Investigational Site | Los Angeles | California | 90095 | — |
| GSK Investigational Site | Stanford | California | 94305-5235 | — |
| GSK Investigational Site | Denver | Colorado | 80218 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| GSK Investigational Site | Jacksonville | Florida | 32207 | — |
| GSK Investigational Site | Miami | Florida | 33155-3009 | — |
| GSK Investigational Site | Orlando | Florida | 32835 | — |
| GSK Investigational Site | Tallahassee | Florida | 32308 | — |
| GSK Investigational Site | Tampa | Florida | 33609 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Augusta | Georgia | 30912 | — |
| GSK Investigational Site | Lexington | Kentucky | 40536-0284 | — |
| GSK Investigational Site | Saint Paul | Minnesota | 55102-2383 | — |
| GSK Investigational Site | Columbia | Missouri | 65211 | — |
| GSK Investigational Site | Kansas City | Missouri | 64108 | — |
| GSK Investigational Site | Cherry Hill | New Jersey | 8034 | — |
| GSK Investigational Site | Buffalo | New York | 14222 | — |
| GSK Investigational Site | Mineola | New York | 11501 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27607 | — |
| GSK Investigational Site | Akron | Ohio | 44308-1062 | — |
| GSK Investigational Site | Cleveland | Ohio | 44106 | — |
| GSK Investigational Site | Columbus | Ohio | 43205 | — |
| GSK Investigational Site | Portland | Oregon | 97201-2884 | — |
| GSK Investigational Site | Portland | Oregon | 97201-2984 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213-2583 | — |
| GSK Investigational Site | Morristown | Tennessee | 37813 | — |
| GSK Investigational Site | Nashville | Tennessee | 37212 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Fort Worth | Texas | 76104 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84113 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22908 | — |
| GSK Investigational Site | Norfolk | Virginia | 23507 | — |
| GSK Investigational Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00044278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 18, 2017 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00044278 live on ClinicalTrials.gov.